Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery

This is not the most recent version

Information

DOI:
https://doi.org/10.1002/14651858.CD009286.pub2Copy DOI
Database:
  1. Cochrane Database of Systematic Reviews
Version published:
  1. 14 November 2012see what's new
Type:
  1. Intervention
Stage:
  1. Review
Cochrane Editorial Group:
  1. Cochrane Stroke Group

Copyright:
  1. Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Article metrics

Altmetric:

Cited by:

Cited 0 times via Crossref Cited-by Linking

Collapse

Authors

  • Gillian E Mead

    Correspondence to: Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK

    [email protected]

    [email protected]

  • Cheng‐Fang Hsieh

    Division of Geriatrics and Gerontology, Department of Internal Medicine and Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

  • Rebecca Lee

    Department of Medicine of the Elderly, Western General Hospital, Edinburgh, UK

  • Mansur A Kutlubaev

    Division of Clinical Neurosciences, Western General Hospital, Edinburgh, UK

  • Anne Claxton

    Department of Neurology, Royal Perth Hospital, Perth, Australia

  • Graeme J Hankey

    Department of Neurology, Royal Perth Hospital, Perth, Australia

  • Maree L Hackett

    Department of Neurological and Mental Health, The George Institute for Global Health, Sydney, Australia

Contributions of authors

Dr Mead, Dr Hackett and Professor Hankey wrote the protocol. Dr Kutlubaev and Dr Lee read the protocol and approved it. All authors contributed to the searches, or selection of trials or data extraction, as indicated in the text. Dr Mead performed the analyses.

Sources of support

Internal sources

  • None, Not specified.

External sources

  • Stroke Research Network, UK.

    Stroke Research Network in England provided some financial support to the Cochrane Stroke Group for assistance with the searches

  • Scotland, Not specified.

    Scottish Stroke Research Network provided some funding to the Cochrane Stroke group for assistance with the searches

Declarations of interest

Gillian Mead, Maree Hackett and Graeme Hankey are co‐principal investigators on the planned FOCUS trial (Fluoxetine or control under supervision) in the UK and the AFFINITY (Assessment of fluoxetine in stroke recovery) trial in Australia designed to assess the impact of fluoxetine on disability and dependency after stroke. These trials fulfil our inclusion criteria.

Acknowledgements

We are grateful to Brenda Thomas for her assistance in devising the search strategy, and to the editorial and peer reviewers Peter Langhorne, Brenda Thomas, Ashma Krishnan and Robert Robinson. We are grateful to Ms Maureen Harding for assisting to retrieve papers. We are grateful to Dr Maria Corretge for translating an Italian paper that was subsequently not eligible, and to Dr William Whitely for assistance with extracting data from a paper written in German. Dr Matthew Harris performed citation searches for three papers. We are grateful to Professor Maarten IJzerman for responding to our request for further information about the flu2066 and flu 2008 trials.

We are grateful to the peer reviewers (Peter Langhorne, Brenda Thomas, Andrew Herxheimer, Craig Anderson, Ashma Krishan) for their most helpful comments, and also to Dr Raghda Rashad who provided feedback from a consumer perspective.

Version history

Published

Title

Stage

Authors

Version

2021 Nov 15

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery

Review

Lynn A Legg, Ann-Sofie Rudberg, Xing Hua, Simiao Wu, Maree L Hackett, Russel Tilney, Linnea Lindgren, Mansur A Kutlubaev, Cheng-Fang Hsieh, Amanda J Barugh, Graeme J Hankey, Erik Lundström, Martin Dennis, Gillian E Mead

https://doi.org/10.1002/14651858.CD009286.pub4

2019 Nov 26

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery

Review

Lynn A Legg, Russel Tilney, Cheng‐Fang Hsieh, Simiao Wu, Erik Lundström, Ann‐Sofie Rudberg, Mansur A Kutlubaev, Martin Dennis, Babak Soleimani, Amanda Barugh, Maree L Hackett, Graeme J Hankey, Gillian E Mead

https://doi.org/10.1002/14651858.CD009286.pub3

2012 Nov 14

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery

Review

Gillian E Mead, Cheng‐Fang Hsieh, Rebecca Lee, Mansur A Kutlubaev, Anne Claxton, Graeme J Hankey, Maree L Hackett

https://doi.org/10.1002/14651858.CD009286.pub2

2011 Nov 09

Selective serotonin reuptake inhibitors (SSRIs) for stroke

Protocol

Gillian E Mead, Graeme J Hankey, Mansur A Kutlubaev, Rebecca Lee, Matthew Bailey, Maree L Hackett

https://doi.org/10.1002/14651858.CD009286

Differences between protocol and review

We had planned to search the Organon and Wyeth pharmaceutical websites, but when the searches were done, these websites no longer existed. We decided to search the Lundbeck website as this company makes citalopram.

We had planned to search www.ClinicalStudyResults.org, but this was removed from the Internet in 2011.

We stated that we would include trials in which patients were recruited within three months of stroke onset. However, when we started our searches, we identified several trials in which patients had been recruited after three months. In order to ensure that our review provides a complete as possible picture about the role of SSRIs for stroke recovery, we decided to include trials in which the mean time since stroke onset was less than one year, and to perform subgroup analyses to explore the effect of time since onset on effect sizes. This decision was made before any data extraction and analysis had been performed.

We stated that two review authors would independently scrutinise the full‐text articles retrieved from the searches, but this was not possible for the main MEDLINE and EMBASE searches because of the large number of full texts retrieved; for these searches, one experienced review author (GM) scrutinised the full texts.

We also stated that two review authors would extract data. Several of our included trials had already been included in other Cochrane reviews led by Dr Hackett, one of our review authors. For these trials, only one additional review author extracted data and checked this against the data extraction that had previously been performed for the previous reviews.

We had not anticipated such as large number of Chinese studies. An additional review author joined the team to perform data extraction for these Chinese papers, but we could not find a second independent reviewer who was sufficiently fluent in Chinese to perform data extraction.

We had intended to use random‐effects models only if there was evidence of statistical heterogeneity. Following editorial review, we use random‐effects models for all our analyses.

We extracted data on sources of funding, and included this as part of risk of bias assessment.

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.